Filing Flows › Journey Medical (DERM) › Q4 2025
Journey Medical (DERM) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 26, 2026
Journey Medical (DERM) reported revenue of $16.1M for the fourth quarter 2025 (Q4 2025), +18% from a year earlier and -9% from the quarter before. Operating margin was -2.8%, net loss $1.2M (7.8% of revenue).
Journey Medical, Q4 2025: revenue $16.1M (+18% year over year), operating margin -2.8%, net loss $1.2M, operating cash flow −$6.3M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $16.1M | -9% | +18% |
| Operating profit | −$443K | — | -120% |
| Net earnings | −$1.2M | — | -182% |
| Operating cash flow | −$6.3M | — | -382% |
What changed
Revenue was $16.1M in Q4 2025, up 18% year over year and down 9% from the previous quarter. Qbrexza was the largest line at 34% of revenue.
Operating costs exceeded revenue by $443K, an operating margin of -2.8%. Total costs grew 45% against revenue growth of 18%. The quarter ended with a net loss of $1.2M, narrower than the previous quarter's $2.3M loss. Net interest and other expense of $804K was the main reason.
Operating cash flow was −$6.3M. Non-cash charges added back $1.8M of share-based compensation. Working capital and other items used $6.8M.
Questions
What was Journey Medical's revenue in the fourth quarter 2025?
Journey Medical (DERM) reported revenue of $16.1M for the fourth quarter 2025 (Q4 2025), +18% from a year earlier and -9% from the quarter before.
Was Journey Medical profitable in the fourth quarter 2025?
Operating loss was $443K (-2.8% of revenue) and net loss $1.2M.
Source: Journey Medical 10-K on SEC EDGAR.